Faizan Bashir

Dr. Faizan Bashir

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
ETEhab Ayman Takrori
Ehab Ayman Takrori
NKNaga Anvesh Kodali
Naga Anvesh Kodali
FBFaizan Bashir
Faizan Bashir
SSSakshi Singal
Sakshi Singal
Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy with rising incidence and dismal long-term survival, largely due to late-stage presentation and intrinsic resistance to therapy. Recent advances in the multidisciplinary management of PDAC have reshaped treatment paradigms across disease stages. For localized disease, innovations in surgical techniques and the adoption of neoadjuvant strategies have improved resection rates and survival outcomes. In metastatic settings, multiagent chemotherapy regimens and precision therapies targeting BRCA mutations and rare gene fusions are expanding treatment options. Immunotherapeutic modalities, including checkpoint inhibitors, adoptive cell therapies, and mRNA vaccines, show emerging promise despite PDAC’s traditionally immunosuppressive microenvironment. This review synthesizes the current evidence on established therapies and critically evaluates novel and investigational approaches poised to redefine the therapeutic landscape of pancreatic cancer.

11 July 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
FBFaizan Bashir
Faizan Bashir
NKNaga Anvesh Kodali
Naga Anvesh Kodali
ADAdit Dharia
Adit Dharia
SZSajida Zaiter
Sajida Zaiter
NMNagaishwarya Moka
Nagaishwarya Moka
Immunotherapy has emerged as a transformative approach in gastrointestinal (GI) cancers, addressing historically poor survival rates in advanced-stage disease. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis demonstrate remarkable efficacy in colorectal cancer with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), exemplified by trials like NICHE-2 achieving exceptional pathological response rates. However, significant limitations persist, including resistance in some dMMR/MSI-H tumors, minimal efficacy in proficient mismatch repair (pMMR) tumors, and low overall response rates across most GI malignancies due to tumor heterogeneity and immune evasion mechanisms. Predictive biomarkers such as tumor mutational burden (TMB) and PD-L1 expression are crucial for optimizing patient selection, while hypermutated pMMR tumors with POLE mutations represent emerging therapeutic opportunities. In pancreatic adenocarcinoma, where survival remains dismal, combination strategies with chemotherapy and novel approaches like cancer vaccines show promise but lack transformative breakthroughs. Esophagogastric cancers benefit from ICIs combined with chemotherapy, particularly in MSI-H and HER2-positive tumors, while hepatocellular carcinoma has achieved significant progress with combinations like atezolizumab–bevacizumab and durvalumab–tremelimumab surpassing traditional therapies. Biliary tract cancers show modest improvements with durvalumab–chemotherapy combinations. Despite these advances, immunotherapy faces substantial challenges including immune-related adverse events, acquired resistance through cancer immunoediting, and the need for biomarker-driven approaches to overcome tumor microenvironment barriers. This review discusses key clinical trials, therapeutic progress, and emerging modalities including CAR T-cell therapies and combination strategies, emphasizing the critical need to address resistance mechanisms and refine precision medicine approaches to fully realize immunotherapy’s potential in GI malignancies.

1 February 2026 in Health Science Reports
Verified
Journal Article
Open access
MMMaryam Mohammadi
Maryam Mohammadi
PPParsa Panahiyan
Parsa Panahiyan
FBFaizan Bashir
Faizan Bashir
SHShayesteh Haghighi
Shayesteh Haghighi
SASara Ahmadi
Sara Ahmadi
DYDanyal Yarahmadi
Danyal Yarahmadi
Background: Type 2 diabetes mellitus (T2DM) is increasingly seen as a chronic inflammatory state, with the neutrophil‐to‐lymphocyte ratio (NLR) studied as a new biomarker of systemic inflammation. Evidence links NLR to glycemic control, but its consistency and strength vary. This review summarizes data on NLR's relationship with glycemic indicators, such as hemoglobin A1c (HbA1c), across different T2DM glycemic states. Methods: A systematic literature search was carried out in PubMed/MEDLINE, Scopus, Web of Science, and Embase through November 2025 to find studies that reported both NLR and glycemic control indicators in adults with T2DM. Data were systematically extracted based on predefined criteria. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were combined using random‐effects models. Heterogeneity was measured using the I² statistic, and robustness was assessed using sensitivity analyses. Publication bias was investigated using Begg's and Egger's tests, trim‐and‐fill analysis, and funnel plot examination. All statistical analyses were conducted using STATA 18 (StataCorp, College Station, TX, USA). Results: The meta‐analysis consisted of 27 studies (37 comparisons) with a total of 48,714 individuals from 11 nations. NLR demonstrated a stepwise gradient with deteriorating glycemic control: poorly controlled T2DM (HbA1c > 7%) had higher NLR than well‐controlled T2DM (HbA1c ≤ 7%) ( p < 0.001), prediabetes (HbA1c 5.7–6.4%) ( p < 0.001), and normoglycemia (HbA1c ≤ 5.7%) ( p = 0.037). Conclusions: NLR rises progressively with deteriorating glycemic control and is markedly raised in poorly controlled T2DM. These observations endorse NLR as an inexpensive, widely available inflammatory biomarker that can augment conventional glycemic measures in the clinical setting.

18 February 2025 in BMC Rheumatology
Verified
Journal Article
Open access
PDF file
FBFaizan Bashir
Faizan Bashir
MBMoiza Bashir
Moiza Bashir
MRMoniza Rafiq
Moniza Rafiq
AJAli Jafer
Ali Jafer
SHSaide Honarmand
Saide Honarmand
IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition characterized by elevated IgG4 serum levels and tissue infiltration by IgG4-positive plasma cells. While often presenting with organ-specific involvement, such as sialadenitis or pancreatitis, its rheumatologic manifestations are rare and poorly understood. IgG4-RD often overlaps with autoimmune diseases such as rheumatoid arthritis (RA), posing a diagnostic challenge, particularly in seronegative presentations. We report a 48-year-old male presenting with progressive symmetrical polyarthritis mimicking rheumatoid arthritis. Laboratory findings showed elevated serum IgG4 levels and inflammatory markers, while autoantibodies (RF, ACPA, ANA, ANCA) were negative. A biopsy of a submandibular gland revealed dense lymphoplasmacytic infiltrates + fibrosis and IgG4-positive plasma cells, confirming the diagnosis of IgG4-RD. The patient responded well to a combination of glucocorticoids and methotrexate, with complete symptom resolution within one month and normalization of inflammatory markers.The therapeutic response observed in this case demonstrates the effectiveness of immunosuppression therapy in IgG4-RD management, while emphasizing the need for long-term follow-up. This case underscores the diagnostic challenges in recognizing arthritis in a patient with biopsy-confirmed IgG4-related sialadenitis particularly when seronegative rheumatoid arthritis (RA) remains a plausible differential diagnosis.The overlapping clinical features and shared treatment responses make it challenging to attribute the arthritis to a single etiology.This report emphasizes the importance of considering IgG4-RD in the differential diagnosis of atypical arthritis presentations, particularly in patients with systemic manifestations. Histopathological confirmation, supported by clinical and serological evaluation, remains pivotal in guiding diagnosis and management. Long-term follow-up is essential to monitor for evolving features, including the potential development of overlapping conditions, and to ensure optimal treatment outcomes. Early recognition and tailored interventions are critical to preventing complications and improving patient quality of life. IgG4-related disease (IgG4-RD) must be considered in the differential diagnosis of seronegative arthritis, especially when systemic symptoms or organ involvement are present. This case underscores the growing recognition of IgG4-RD in rheumatologic practice and the importance of a multidisciplinary approach to diagnosis and management. Clinicians should maintain heightened awareness of the overlap between IgG4-RD and rheumatoid arthritis (RA), advocating for the integration of histopathology, imaging, and serological testing to ensure accurate diagnosis. Additionally, long-term follow-up is essential to monitor disease progression, recurrence, development of new symptoms, and treatment response, ultimately enhancing patient care and outcomes.

Verified
Journal Article
Open access
PDF file
SPSupriya Peshin
Supriya Peshin
ETEhab Ayman Takrori
Ehab Ayman Takrori
NKNaga Anvesh Kodali
Naga Anvesh Kodali
FBFaizan Bashir
Faizan Bashir
Michael K GibsonMichael K Gibson
Michael K Gibson
SSSakshi Singal
Sakshi Singal
Gastroesophageal cancer (GEC) represents a global health burden, with rising incidence and high mortality. Despite advancements in early detection and systemic therapies, outcomes remain poor, especially in advanced stages. Management requires a multidisciplinary, multimodal approach that integrates surgery, chemotherapy, radiotherapy, targeted agents, and immunotherapy, tailored by tumor histology, location, and molecular profile. For localized disease, perioperative chemotherapy or chemoradiotherapy is standard, with adjuvant immunotherapy now emerging in selected high-risk cases. In metastatic or unresectable settings, systemic therapy forms the backbone of treatment, with biomarker-driven regimens targeting HER2, PD-L1, MSI-H/dMMR, and CLDN18.2, offering improved outcomes. Novel agents and combinations, including bispecific antibodies, FGFR2 inhibitors, and immunotherapy-based strategies, are actively being explored in clinical trials. This review provides a comprehensive overview of the evolving therapeutic landscape of GEC. It emphasizes the growing role of precision medicine and the integration of emerging clinical data into practice.

3 October 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
DDDorna Derakhshan
Dorna Derakhshan
SGShabnam Hajiani Ghotbabadi
Shabnam Hajiani Ghotbabadi
FMFatemeh Mazarei
Fatemeh Mazarei
AMAli Mirzakhanlouei
Ali Mirzakhanlouei
FBFaizan Bashir
Faizan Bashir
Background: Nocturnal Enuresis (NE) is a prevalent childhood condition with a multifactorial pathogenesis comprising genetic, neurological, and connective tissue factors. Recent evidence points toward a possible link between joint hypermobility and NE, but the underlying mechanisms remain unclear, and existing data are limited. The objective of this study is to determine the prevalence of joint hypermobility in patients with primary nocturnal enuresis (PNE) relative to healthy controls and investigate potential correlations between these conditions. Methods: This cross-sectional study was conducted in 2024 at Imam Reza Clinic, the largest pediatric outpatient clinic affiliated with Shiraz University of Medical Sciences in Shiraz, Iran. A total of 180 children aged 6–13 years were recruited, including 90 children with primary nocturnal enuresis (study group) and 90 healthy children without nocturnal enuresis (control group). Participants were assessed for generalized joint hypermobility (GJH) using the Beighton score (≥ 6 indicating hypermobility). Demographic and clinical information was gathered on structured checklists. Statistical tests, such as chi-square tests, t-tests, and logistic regression, were carried out using SPSS (version 25) at a significance level of p < 0.05. Results: The prevalence of joint hypermobility was significantly higher in children with NE (87.8%) than in controls (28.9%) (p < 0.0001). Conversely, NE was present in 75.2% of hypermobile children compared with 14.7% of non-hypermobile children (p < 0.0001). Logistic regression analysis revealed that children with nocturnal enuresis were 19.87 times more likely to have joint hypermobility compared to non-enuretic children following the adjustment for age, gender, and BMI (p < 0.05). Gender-specific analysis indicated that hypermobile girls with nocturnal enuresis at a greater likelihood of suffering from urinary incontinence and frequent urinary tract infections (UTIs), whereas hypermobile boys with nocturnal enuresis had increased rates of constipation and urinary symptoms during the day. Conclusion: This study shows a strong association between GJH and PNE. Further research is needed to determine causal direction and underlying mechanisms.